$ 5,209,250

$ 4,486,120

128,000

338,000

Upfront license fee

$ 24,000

Research and development expense

$ 430,000

$ 250,000

Research and development expense

$ 7,600,000

License costs

23,000

94,000

Agreement term payment, description

In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.

Revenue

500,000,000

$ 500,000,000

Upfront license fee

20,000

Upfront license fee

100,000

Reimbursement of research expenses

$ 805,000

Marketing approval expenses

$ 500,000

200,000

5,000,000

10,000

5,000,000

Research and development expense

$ 743,000

$ 758,000

Reimbursement of patent

$ 150,000

Milestone payment

50,000

100,000

Milestone payment

100,000

200,000

Milestone payment

$ 150,000

$ 350,000

RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended							12 Months Ended		47 Months Ended
	Jul. 31, 2023	Dec. 31, 2022	Jan. 31, 2022	Nov. 30, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Apr. 30, 2022
Research and development expense								$ 5,209,250	$ 4,486,120
Proceeds from convertible debt		$ 3,000,000.0
License Agreement [Member]
Reimbursement of patent			$ 160,000
License costs								128,000	338,000
License Agreement [Member] \| University of Louisville Research Foundation [Member]
Upfront license fee						$ 24,000
License Agreement [Member] \| University of Louisville Research Foundation [Member] \| Minimum [Member]
Research and development expense				$ 430,000		$ 250,000
Master Laboratory Services Agreement [Member] \| MLM Medical Labs [Member]
Research and development expense	$ 7,600,000
Sponsored Research and License Agreement [Member]
License costs								23,000	94,000
Research and development expense								0	164,000
Sponsored Research and License Agreement [Member] \| University of Louisville Research Foundation [Member]
Reimbursement of research expenses							$ 693,000	2,900,000
Agreement term payment, description					In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
Marketing approval expenses					$ 300,000
Revenue					500,000,000					$ 500,000,000
Sponsored Research and License Agreement [Member] \| University of Louisville Research Foundation [Member] \| Minimum [Member]
Upfront license fee					20,000
Sponsored Research and License Agreement [Member] \| University of Louisville Research Foundation [Member] \| Maximum [Member]
Upfront license fee					100,000
License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member]
Reimbursement of research expenses										$ 805,000
Agreement term payment, description										In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
Marketing approval expenses										$ 500,000
Proceeds from convertible debt										50,000
Patent costs										200,000
License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member] \| Licensed Product Sales [Member]
Cumulative sales					5,000,000					5,000,000
Regulatory marketing approval, expenses										500,000
License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member] \| Minimum [Member]
Milestone payment					50,000					100,000
Shortfall payments										10,000
License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member] \| Maximum [Member]
Milestone payment					5,000,000					5,000,000
Shortfall payments										50,000
Sponsored Research Agreements And License [Member]
License costs								133,000	40,000
Research and development expense								$ 743,000	$ 758,000
Upfront Payment [Member] \| License Agreement [Member]
Reimbursement of patent			$ 150,000
Phase 1 Clinical Trial [Member] \| License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member]
Milestone payment					50,000					100,000
Phase 2 Clinical Trial [Member] \| License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member]
Milestone payment					100,000					200,000
Phase 3 Clinical Trial [Member] \| License and Sponsored Research Agreements [Member] \| University of Louisville Research Foundation [Member]
Milestone payment					$ 150,000					$ 350,000